Welcome to Pharmaceutical Executive Daily, your quick briefing on the top news shaping the pharmaceutical and life sciences ...

Jun Gong, MD, associate professor of medicine and medical director of colorectal cancer at Cedars-Sinai, spoke with ...

With healthcare costs dominating the conversation in recent years, the topic of employer-covered healthcare is a key issue.

FDA cleared belzutifan 120 mg plus lenvatinib 20 mg daily for advanced RCC with a clear cell component after prior PD-1/PD-L1 inhibitor exposure. LITESPARK-011 randomized 747 patients to ...

FDA authorization is underpinned by four global Phase III QWINT studies showing non-inferior A1C lowering versus glargine ...

Novo Nordisk secured Pharmashell access for up to five peptide programs, targeting long-acting injectable profiles and offering Nanexa >$1.33B total consideration plus low single-digit royalties.

Self-reported histories at enrollment are costly due to collection burden and frequent inaccuracies, which can drive mis-enrollment, audits, exclusions, and potentially serious safety signals that ...

As GLP-1 competition shifts from molecules to prescriptions, manufacturers, pharmacies, providers, and payers are racing to ...

Chief executives from nine of Europe's largest drugmakers are calling on the European Union (EU) and its member states to ...

EVERSANA's Jen Norton talks about how AI is reshaping market access strategy, a new analysis from MIT and Harvard Business ...

GSK is acquiring a trispecific T-cell engager from Chimagen Biosciences and Sanofi expanding its manufacturing partnership ...

The agreement provides up to $100 million upfront/near-term and up to ~$3.25 billion in milestones, plus single-digit tiered royalties, reflecting high optionality typical of early discovery ...